Icenticaftor Effective in CF Patients With Certain Mutations, Phase 1/2 Trial Shows
Experimental therapy icenticaftor (QBW251) was able to improve lung function in cystic fibrosis (CF) patients carrying class 3 and 4 mutations in the CFTR gene, results from a Phase 1/2 trial show. It also appeared to be safe and well tolerated when given to both healthy volunteers and CF…